Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Korro Bio (KRRO) EBT (2019 - 2025)

Korro Bio (KRRO) has disclosed EBT for 6 consecutive years, with -$18.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT rose 14.03% year-over-year to -$18.1 million, compared with a TTM value of -$88.3 million through Sep 2025, down 556.31%, and an annual FY2024 reading of -$83.4 million, changed N/A over the prior year.
  • EBT was -$18.1 million for Q3 2025 at Korro Bio, up from -$25.8 million in the prior quarter.
  • Across five years, EBT topped out at $48.9 million in Q4 2023 and bottomed at -$25.8 million in Q2 2025.
  • Average EBT over 5 years is -$15.4 million, with a median of -$20.4 million recorded in 2021.
  • The sharpest move saw EBT plummeted 372.25% in 2021, then skyrocketed 687.88% in 2023.
  • Year by year, EBT stood at -$21.5 million in 2021, then surged by 128.86% to $6.2 million in 2022, then surged by 687.88% to $48.9 million in 2023, then tumbled by 143.15% to -$21.1 million in 2024, then increased by 14.39% to -$18.1 million in 2025.
  • Business Quant data shows EBT for KRRO at -$18.1 million in Q3 2025, -$25.8 million in Q2 2025, and -$23.4 million in Q1 2025.